KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 11.08 CNY -0.27% Market Closed
Market Cap: ¥8.4B

P/OCF

29
Current
48%
More Expensive
vs 3-y average of 19.6

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
29
=
Market Cap
¥8.5B
/
Operating Cash Flow
¥289.2m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
29
=
Market Cap
¥8.5B
/
Operating Cash Flow
¥289.2m

Valuation Scenarios

KPC Pharmaceuticals Inc is trading above its 3-year average

If P/OCF returns to its 3-Year Average (19.6), the stock would be worth ¥7.49 (32% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-37%
Maximum Upside
+13%
Average Downside
18%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 29 ¥11.08
0%
3-Year Average 19.6 ¥7.49
-32%
5-Year Average 32.7 ¥12.49
+13%
Industry Average 25 ¥9.56
-14%
Country Average 18.3 ¥6.98
-37%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CN
KPC Pharmaceuticals Inc
SSE:600422
8.4B CNY 29 24
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 49.7 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 22.3 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 19.7 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 14.3 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 16.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 13.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.3 16.8
P/E Multiple
Earnings Growth PEG
CN
KPC Pharmaceuticals Inc
SSE:600422
Average P/E: 22.1
24
10%
2.4
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in China
Percentile
64rd
Based on 6 232 companies
64rd percentile
29
Low
0.2 — 9.8
Typical Range
9.8 — 36.5
High
36.5 —
Distribution Statistics
China
Min 0.2
30th Percentile 9.8
Median 18.3
70th Percentile 36.5
Max 266 666.7

KPC Pharmaceuticals Inc
Glance View

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
10.17 CNY
Overvaluation 8%
Intrinsic Value
Price ¥11.08
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett